Typ-1-Narkolepsie – die späte Diagnose

ARSALAN JAFARPOUR; MATTHIAS BOENTERT; PETER YOUNG

doi:10.1055/s-0038-1626143

Schlaf, Inhaltsverzeichnis

Schlaf 2015; 04(03): 147-153
DOI: 10.1055/s-0038-1626143

Kasuistik

Schattauer GmbH

Typ-1-Narkolepsie – die späte Diagnose

Fallbericht und Krankheitsbild

ARSALAN JAFARPOUR

,

MATTHIAS BOENTERT

,

PETER YOUNG

Abstract

Das Manifestationsalter für Narkolepsie zeigt zwei Erkrankungsgipfel: während der Pubertät und um das 35. Lebensjahr. Sehr selten erkranken Patienten nach dem 40. Lebensjahr. Wir beschreiben den Fall einer 75-jährigen Patientin, die mit etwa 45 Jahren an Narkolepsie erkrankte und erst dreißig Jahre später die Diagnose zur Typ-1-Narkolepsie erhielt.

Volltext

Referenzen

Literatur
1 Wright KP, Lowry CA, Lebourgeois MK. Circadian and wakefulness-sleep modulation of cognition in humans. Frontiers in molecular neuroscience 2012; 5: 50.
2 Ackermann K, Stehle JH. Melatonin synthesis in the human pineal gland: advantages, implications, and difficulties. Chronobiol Int 2006; 23 (1–2) 369-379.
3 Markov D, Goldman M. Normal sleep and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. The Psychiatric clinics of North America 2006; 29 (04) 841-853 abstract vii.
4 Kalsbeek A, van der Spek R, Lei J. et al. Circadian rhythms in the hypothalamo-pituitary-adrenal (HPA) axis. Molecular and cellular endocrinology 2012; 349 (01) 20-29.
5 Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends in neuro sciences 2001; 24 (12) 726-731.
6 Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437 (7063) 1257-1263.
7 Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of Hypokretin neurons. Nature 2007; 450 (7168) 420-424.
8 Carter ME, Yizhar O, Chikahisa S. et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nature neuroscience 2010; 13 (12) 1526-1533.
9 de Lecea L, Carter ME, Adamantidis A. Shining light on wakefulness and arousal. Biological psychiatry 2012; 71 (12) 1046-1052.
10 Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypokretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. The Lancet Neurology 2015; 14 (03) 318-328.
11 Partinen M, Kornum BR, Plazzi G. et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. The Lancet Neurology 2014; 13 (06) 600-613.
12 Wijnans L, Lecomte C, de Vries C. et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31 (08) 1246-54.
13 Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophys 2001; 18 (02) 78-105.
14 American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd. ed. Sateia M. (ed.) Darien, IL/USA: 2014: 383.
15 Dauvilliers Y, Siegel JM, Lopez R. et al. Cataplexy--clinical aspects, pathophysiology and management strategy. Nature reviews Neurology 2014; 10 (07) 386-395.
16 Longstreth Jr. WT, Koepsell TD, Ton TG. et al. The epidemiology of narcolepsy. Sleep 2007; 30 (01) 13-26.
17 Mayer G. [Narcolepsy]. Der Nervenarzt. 2014; 85 (01) 26 8–34.
18 Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002; 25 (02) 197-202.
19 Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369 (9560) 499-511.
20 Rye DB, Dihenia B, Weissman JD, Epstein CM, Bliwise DL. Presentation of narcolepsy after 40. Neurology 1998; 50 (02) 459-465.
21 Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep medicine 2004; 5 (01) 37-41.
22 Suzuki S, Uehara T, Ohira Y, Ikusaka M. Narcolepsy with Cataplexy in an Elderly Woman. J Genl Int Med. 2015 ■
23 Kovac S, Diehl B. Atonic phenomena in focal seizures: nomenclature, clinical findings and pathophysiological concepts. Seizure 2012; 21 (08) 561-567.
24 Saperstein DS. Muscle channelopathies. Seminars in neurology 2008; 28 (02) 260-269.
25 Ford ES, Cunningham TJ, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep medicine 2015; 16 (03) 372-378.
26 Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Excessive daytime sleepiness and body composition: a population-based study of adults. PloS one 2014; 9 (11) e112238.
27 Bodkin CL, Manchanda S. Office evaluation of the „tired“ or „sleepy“ patient. Seminars in neurology 2011; 31 (01) 42-53.
28 Mitchell GMKCA. Daytime Sleepiness. Sleep Med Clin 2014; 9: 491-198.
29 Dauvilliers Y. Differential diagnosis in hypersomnia. Current neurology and neuroscience reports 2006; 6 (02) 156-162.
30 Guilleminault C, Brooks SN. Excessive daytime sleepiness: a challenge for the practising neurologist. Brain 2001; 124 (Pt 8) 1482-91.
31 Chakravorty SS, Rye DB. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs & aging 2003; 20 (05) 361-376.
32 Marti I, Valko PO, Khatami R, Bassetti CL, Baumann CR. Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep medicine 2009; 10 (10) 1146-1150.
33 Drakatos P, Kosky CA, Higgins SE, Muza RT, Williams AJ, Leschziner GD. First rapid eye movement sleep periods and sleep-onset rapid eye movement periods in sleep-stage sequencing of hypersomnias. Sleep medicine 2013; 14 (09) 897-901.
34 Andlauer O, Moore H, Jouhier L, Drake C, Peppard PE, Han F. et al. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/Hypokretin deficiency. JAMA neurology 2013; 70 (07) 891-902.
35 Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A. et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. The Lancet Neurology 2013; 12 (11) 1068-1075.
36 Becker HFF J, Fietze I, Geisler P, Happe S. et al. S3-Leitlinie-Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 2009; 13 (Suppl. 01) 4-160.
37 Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. The Journal of neuroscience 2012; 32 (36) 12305-12311.
38 Oberle D, Mayer G, Keller-Stanislawski B. Narkolepsie nach Impfung gegen die pandemische Influenza A/H1N1/v?. Schlaf 2013; 3: 154-160.